Everolimus (RAD001)
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Conditions
Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Trial Timeline
Apr 1, 2012 → Apr 1, 2015
NCT ID
NCT01365468About Everolimus (RAD001)
Everolimus (RAD001) is a phase 2 stage product being developed by Novartis for Plexiform Neurofibroma Associated With Neurofibromatosis Type 1. The current trial status is terminated. This product is registered under clinical trial identifier NCT01365468. Target conditions include Plexiform Neurofibroma Associated With Neurofibromatosis Type 1.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01514448 | Approved | Completed |
| NCT01365468 | Phase 2 | Terminated |
| NCT01595009 | Approved | Completed |
| NCT01152801 | Phase 1 | Completed |
| NCT01022996 | Phase 2 | Completed |
| NCT00792766 | Phase 1/2 | Completed |
| NCT00426530 | Phase 1 | Completed |
| NCT00419159 | Phase 2 | Completed |
| NCT00154297 | Approved | Completed |
| NCT00170794 | Phase 3 | Completed |
| NCT00531440 | Phase 3 | Completed |
| NCT00531063 | Phase 3 | Completed |
Competing Products
2 competing products in Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Treatment A + Treatment B + Treatment C + Treatment D + Acetaminophen | AstraZeneca | Phase 1 | 33 |